Head-to-head evidence
UIC201604 vs Zhibitai
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: HMG-CoA reductase · full Atherosclerotic Cardiovascular Disease pipeline
UIC201604
Developed by Korea United Pharm
NCT07600385 · Phase 3 · completed
The study randomized 260 participants to UI022/UI023 or an active comparator and masked both participants and investigators. Its primary endpoint was change in the KPAQ summary score at week 24. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Zhibitai
Developed by Chengdu Diao Jiuhong Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: UIC201604's landscape · Zhibitai's landscape